Trinity Industries, Inc. Announces First Quarter 2024 Results
Reports both quarterly GAAP and adjusted earnings from continuing operations of $0.33 per diluted share Lease fleet utilization of 97.5% and Future Lease Rate Differential... Read more.
KKR & Co. Inc. Reports First Quarter 2024 Results
NEW YORK–(BUSINESS WIRE)–KKR & Co. Inc. (NYSE: KKR) today reported its first quarter 2024 results, which have been posted to the Investor Center... Read more.
Phreesia’s Alicia Cowley and Natasha Vega Named to MM+M’s ‘Women to Watch’ for 2024
ALL-REMOTE COMPANY/WILMINGTON, Del.–(BUSINESS WIRE)–Phreesia is pleased to announce that the healthcare marketing industry trade publication MM+M has... Read more.
The Estée Lauder Companies Reports Fiscal 2024 Third Quarter Results
Net Sales Increased 5% and Diluted EPS Increased to $.91 Organic Net Sales1 Grew 6% and Adjusted Diluted EPS Increased to $.97 Asia Travel Retail Returned to Net... Read more.
Pfizer Reports First-Quarter 2024 Results
Solid First-Quarter Results Reflect Continued Growth of Key Products and Progress in Executing 2024 Priorities First-Quarter 2024 Revenues of $14.9 Billion Expected... Read more.
ATS To Host Fourth Quarter Earnings Call Thursday May 16, 2024, at 8:30 a.m. Eastern
CAMBRIDGE, Ontario–(BUSINESS WIRE)–ATS Corporation (TSX: ATS) (NYSE: ATS) (“ATS” or the “Company”) will report its financial results for the... Read more.
IDEXX Laboratories Announces First Quarter Results
Achieves first quarter revenue growth of 7% as reported and organic, supported by CAG Diagnostics recurring revenue growth of 7% as reported and organic Solid growth... Read more.
United Therapeutics Corporation Reports First Quarter 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today... Read more.
ESAB Corporation Announces First Quarter 2024 Results
Record first quarter sales and margin performance EBX expected to drive improved full year margins Strengthened balance sheet with successful bond offering Completed... Read more.
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
– Regulatory filings planned for US, EU, UK and Japan to enable multiple 2025 commercial launches – – Development strategy refined for oral Factor... Read more.